98%
921
2 minutes
20
Objective: The authors describe a transcatheter mitral valve-in-valve-in-valve (VIVIV) for the correction of a degenerated transcatheter in a surgical bioprosthesis, a challenging interventional scenario that will be increasingly frequent in the near future.
Key Steps: The key steps taken were as follows: preprocedural planning integrating data from transesophageal echocardiogram, cardiac computed tomography, and 3mensio reconstruction (Pie Medical Imaging); transfemoral transseptal VIVIV performed with EchoNavigator system (Philips) guidance; Sapien Ultra 3 26-mm valve (Edwards Lifesciences) delivered with buddy balloon maneuvers to uncage the valve from the atrial struts of the previously implanted valve; and atrial septal defect occlusion with the Amplatzer ASO 24 mm (Abbott Cardiovascular).
Potential Pitfalls: The inability to advance the prosthesis into the ventricle, irreversible hemodynamic collapse, residual high transmitral mean gradient because of impingment of the 3 valves, residual paravalvular leaks, and left ventricular outflow tract obstruction.
Take-home Messages: Mitral VIVIV procedures represent a viable option for patients with prohibitive surgical risk and a degenerated transcatheter in surgical bioprostheses. Success hinges on adequate preprocedural planning and a thorough understanding of bailout techniques to minimize failure and prevent major complications.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12046790 | PMC |
http://dx.doi.org/10.1016/j.jaccas.2025.103398 | DOI Listing |
Struct Heart
September 2025
Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland, Ohio, USA.
Background: Leaflet thrombosis and transcatheter heart valve dysfunction are key concerns following transcatheter aortic valve replacement (TAVR). Prolonged neo-sinus washout time (NWT) may predispose patients to hypoattenuated leaflet thickening (HALT) and leaflet thrombosis, increasing the risk of valve degeneration. This study evaluates the association between in vivo NWT derived from aortograms using computer vision and hemodynamic outcomes at 30 days and 1 year post-TAVR.
View Article and Find Full Text PDFJACC Cardiovasc Interv
August 2025
Division of Cardiothoracic Surgery, Washington University in St. Louis, St. Louis, Missouri, USA.
Background: Aortic valve-in-valve (AViV) replacement for is approved for patients with degenerated surgical valves at high or prohibitive surgical risk, mostly on the basis of small series with short-term follow-up.
Objectives: The aim of this study was to analyze the outcomes of AViV therapy using contemporary balloon-expandable valves (BEVs) in a large series with mid-term outcomes.
Methods: BEV AViV patients (June 2015 to December 2023) in the Society for Thoracic Surgeons (STS)/American College of Cardiology TVT (Transcatheter Valve Therapy) Registry were propensity matched to native transcatheter aortic valve replacement (TAVR) patients.
Catheter Cardiovasc Interv
August 2025
MEDICLIN, Herzzentrum Lahr, Lahr, Germany.
We report an interesting complex percutaneous coronary intervention (PCI) case in an 84-year-old male, with typical angina pectoris after previous coronary artery bypass graft (CABG) surgery and coronary double chimney stenting during a transcatheter aortic valve replacement (TAVR)-in-TAVR procedure with double self-expanding transcatheter heart valve (THV) in his degenerated stentless aortic surgical valve bioprosthesis.
View Article and Find Full Text PDFAnn Thorac Surg
August 2025
Department of Thoracic and Cardiovascular Surgery, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio. Electronic address:
Background: To compare durability of mitral valve repair and changes in left ventricular function in patients with degenerative mitral regurgitation due to posterior leaflet prolapse undergoing transcatheter edge-to-edge mitral valve repair or surgical mitral valve repair.
Methods: From 1/1/2014-1/1/2023, 1046 adults underwent successful mitral repair (MR<2+ and mean mitral gradient<10 mmHg at pre-discharge echo) with either transcatheter(n=97, 9%) or surgical(n=949, 91%) mitral repair (leaflet resection+prosthetic annuloplasty) for posterior leaflet prolapse. Longitudinal analysis of postoperative echo data was used to assess durability of repair and temporal ventricular remodeling.
JACC Cardiovasc Interv
August 2025
Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia, USA. Electronic address: